BIOTIE WITHDRAWS NALMEFENE NATIONAL MARKETING

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 28 June, 2007

Based on its new regulatory strategy in the EU BioTie has withdrawn
the UK national marketing authorisation application on nalmefene in
its alcoholism indication to enable a centralised EU-wide
registration procedure in due course.

Biotie announced on 23 May 2007 that to maximise nalmefene's
potential in the treatment of alcoholism Biotie and Lundbeck have
jointly decided to seek marketing authorisation simultaneously in all
27 EU member states via the centralized procedure. To this end,
Lundbeck plans to further strengthen the existing nalmefene
registration dossier in its alcoholism indication with additional
phase III clinical studies. The studies are expected to start in
2008.

BioTie submitted a national marketing authorisation application
regarding nalmefene in the treatment of alcoholism to the UK
Medicines and Healthcare Regulatory Authority (the "MHRA") in
November 2006. A centralised EU-wide registration procedure is not
feasible if the product already has a granted or pending national
marketing authorisation in the EU.

The new regulatory strategy in the EU ensures exploitation in full of
the expected 10-year market exclusivity for nalmefene in the EU. The
market exclusivity period starts from the first granted marketing
authorisation in the EU.


Turku, June 28, 2007


Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa, President and CEO, Biotie Therapies Corp.
tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com
www.biotie.com

Distribution:     Helsinki Stock Exchange
                       Main Media
BIOTIE WITHDRAWS NALMEFENE NATIONAL MARKETING AUTHORISATION APPLICATION IN THE UK TO ENABLE A CENTRALISED EU-WIDE REGISTRATION PROCEDURE
